Delivering Targeted Radioligand Therapy Directly to Cancer's DNA

The FDA has approved multiple radiopharmaceuticals, validating that targeted radioligand therapy works and establishing a new therapeutic category. But every approved approach operates under the same constraint: large radioactive molecules cannot penetrate cell membranes. The category’s current limitation is that it cannot target the nuclear DNA where complete genomic destruction occurs.

Trevarx Biomedical is developing a breakthrough approach by delivering alpha radiation directly to tumor DNA in the nucleus. Current surface-targeted approaches slow disease progression. Targeting alpha radiation emission at the DNA is designed to cause irreversible genomic damage. If this approach succeeds clinically, it becomes the new standard.

This approach comprises three parts: validated targeting, powerful cell-killing, and image-guided accuracy. Our intellectual property covers the core enabling technologies.

Our team of experts and scientific board of advisors look forward to sharing our work with you. With your support, Trevarx aspires to provide potentially life-changing outcomes first for ovarian cancer patients and possibly three with prostate, breast, and neuroendocrine cancers.